FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

OMB APPROVAL							
OMB Number:	3235-0287						
Estimated average burden							
hours per response:	0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*  Maimon Yossi				2. Issuer Name and Ticker or Trading Symbol Protalix BioTherapeutics, Inc. [ PLX ]									Relationship of Reporting Person(s) to Issuer (Check all applicable)     Director     10% Owner							
(Last)	(Fi	,	Middle)	<b>.</b>	3. Dat 05/13		Trar	nsaction (Month/Day/Year)						X Office below	r (give title	Other (sp below)		specify		
C/O PROTALIX BIOTHERAPEUTICS, INC. 2 SNUNIT STREET, SCIENCE PARK, POB 455					4. If A	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable Line)					
(Street)															X Form	Form filed by One Reporting Person Form filed by More than One Reporting				
CARMII	EL L3	3	20100											Form Perso		e than	One Repo	orting		
(City)	(St	ate) (	Zip)																	
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																			
Date						2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction Code (Instr. 8)		4. Securities Acquired ( Disposed Of (D) (Instr. 3 and 5)				Securit Benefic Owned	ies cially		: Direct	7. Nature of Indirect Beneficial Ownership		
									Code	v	Amount (A		) or )	Price	Report Transa	Following Reported Transaction(s) (Instr. 3 and 4)		. 4)	(Instr. 4)	
Common Stock 05/18/2				2009	009			М		40,34	18	A	<b>\$</b> 0.97	2 40	40,348			By trust <sup>(1)</sup>		
Common Stock 05/18/2				2009	009			F		10,34	18	D	\$3.79	3(	0,000			By trust <sup>(1)</sup>		
Common Stock 05/18/2				009				S		30,00	00	D	\$4	0				By trust <sup>(1)</sup>		
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deer Executio if any (Month/I	on Date,	4. Transact Code (In 8)		on of		6. Date Ex Expiration (Month/Da	Dat	е	7. Title and Amount of Securities Underlying Derivative Security (Instr and 4)			8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	y D (I	0. Ownership Form: Direct (D) or Indirect I) (Instr.	Beneficial Ownership	
					Code	v	(A)	(D)	Date Exercisabl		expiration Date	Title	or Nu of	umber						
Stock Options (Right to Buy)	\$0.972	05/18/2009			M		40,348		(2)	0	9/19/2016	Commo Stock	n 40	,348	\$0	453,648 <sup>(3</sup>	3)	D		

## **Explanation of Responses:**

- 1. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee upon the exercise of stock options must be registered in the name of a trustee.
- 2. 25% of the options vested on September 19, 2007. The remaining 75% vest in 12 equal quarterly installments commencing on September 19, 2007.
- 3. Does not include options to purchase 50,000 shares of common stock at an exercise price equal to \$2.65 per share that expire on February 25, 2019 and does not include options to purchase 175,000 shares of common stock at an exercise price equal to \$5.00 per share that expire on February 7, 2018.

<u>/s/ Yossi Maimon</u> <u>05/19/2009</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.